Brad has over 20 years of experience leading and building global drug development and medical affairs teams focused in pain and epilepsy, Currently he is Chief Medical Officer at Rapport Therapeutics. Prior he was Executive Vice President and Chief Medical Officer at Zogenix, President of the Pain Group at Nuvo Research, and Senior Medical Officer for Endo Pharmaceuticals. He and his teams provided clinical and scientific leadership for the development and marketing of rare epilepsy and analgesic medications, including Fintepla®, Lidoderm®, Pennsaid®, and Frova®. Prior to joining industry, Dr. Galer held numerous academic and clinical appointments. He has over 150 publications in epilepsy and pain management. Dr. Galer completed his medical doctorate and a neurology residency at Albert Einstein College of Medicine in New York, and two pain fellowships at Memorial Sloan Kettering Cancer Center in New York and the University of California San Francisco and was on faculty at the University of Washington School of Medicine.